Downliad full text

View the presentation

Share

EXECUTIVE SUMMARY FOR EXPERT REVIEWERS

DOCUMENT B.2 OUTPATIENT TREATMENT PLAN

WHAT – HOW – DATA-to-operate Architecture according to the Vien gut Model: From complex stage control to sustainable maintenance – four treatment phases [4]

Nguyen Dinh Quang • Vien gut Model – March 2026 [4]

1. Problem Statement

The major treatment goals of the Vien gut Model – crystal-free in complicated gout (Goal 1), delaying dialysis for end-stage chronic kidney disease patients with an open window of opportunity (Goal 2), reducing cardiovascular decompensation (Goal 3), and re-compensating liver cirrhosis (Goal 4) – can only be substantially pursued when patients are approached through the WHAT – HOW – DATA-to-operate treatment model [4]. This thinking aligns with the spirit of NICE regarding multimorbidity: not a mechanical summation of single-disease guidelines, but optimizing care, reducing treatment burden, and having a clear coordinator for each patient [4]. Therefore, these treatment goals are not set after many disjointed examinations, but must be initiated from the very first visit [5]. The first visit must be the activation point for the entire integrated operating system – relatively comprehensive examination and diagnosis, identification of pathological spirals, and patient stratification by treatment safety level to choose the appropriate management direction from the start [5].

2. Three-layer Architecture: WHAT – HOW – DATA-to-operate

The outpatient treatment plan in the Vien gut Model is a three-layer structure [5]. Each layer has a distinct and irreplaceable role [5]. The table below summarizes the core content of each layer:

Layer Core Content
WHAT Treatment goals and principles benchmarked from current guidelines: ACR 2020 (gout), KDIGO 2024 (kidney), ESC 2022 (heart), EASL/AASLD (liver) [6].
HOW Clinical operational layer: Clinical Conductor, T1–T4 stratification, polypharmacy management, phase-based scenarios, follow-up rhythm, MDT role, safety referral valve [6].
DATA-to-operate Data set sufficient for action: which target organ is worsening, which spiral is active, whether the patient still has or has lost the window of opportunity, which phase they are in, and if it is time to change phases/refer [6].

This separation of the three layers explains why guidelines (WHAT) alone are insufficient for treating patients with complex multimorbidity: without the HOW layer, physicians know the goals but lack organizational tools; without the DATA-to-operate layer, the system fails to recognize breaking points and windows of opportunity [7]. Vien gut has developed these two layers through 18 years of integrated clinical practice [7].

3. Five Principles for Developing an Outpatient Treatment Plan

Principle Content
1 One patient – one integrated frame of reference: only one Clinical Conductor and one common set of priorities [7].
2 Do not apply single-disease guidelines mechanically: determine if the patient is within, at the margin of, or outside the guideline coverage [8].
3 Prioritize protecting vital organs first, optimize long-term goals later [8].
4 Polypharmacy management is a mandatory component of every treatment plan [8].
5 Decisions based on time-series trends, not single cross-sectional snapshots [8].

These five principles are not administrative conventions but a safety filter: every clinical decision must be checked against them [8]. When a decision violates any principle, the system must stop and re-evaluate before proceeding [8].

4. Structure of Four Treatment Phases

The outpatient treatment plan is organized into four phases [9]. This division into four phases is not for theoretical aesthetics but reflects the 18-year reality of treating complex chronic multimorbidity at Vien gut [9]. Each phase has its own clinical characteristics, objectives, follow-up rhythm, and varying roles for HOW – DATA-to-operate [9].

Phase Main Objective Follow-up Rhythm
Phase 1: Acute Stabilization Control complex developments, re-establish minimum safety margin [9]. Every few days – 2–4 weeks [9].
Phase 2: Titration Maintain stability, prevent re-entry into the spiral, approach verification goals [9]. 3–4 weeks, maximum 3 months [10].
Phase 3: Maintenance Consolidate results, maintain positive trends, reduce risk of relapsing [10]. Maximum 6 months [10].
Phase 4: Crystal-free Evaluation Sustainable maintenance, return to a healthy life [10]. 2–3 months or as needed [10].

Phase 1 (Acute Stabilization) is the most demanding operationally [10]. In this phase, the disease is still complex, the physician is just starting trial treatments, and patients/relatives are still struggling to understand and implement the plan [10]. HOW must have pre-established backup scenarios for common complex developments [10]. From Phase 2 onwards, the focus shifts from emergency control to maintaining stability and standardized patient training [11]. Phase 4 does not mean the end of treatment, but a transition to sustainable maintenance [11].

5. Clinical Illustration – Case DTH: Four phases in a 4-year case / 46 visits

Case DTH (male, 58 years old, gout ~20 years, cirrhosis F4 Child–Pugh B + CKD G5 + adrenal insufficiency + anemia Hb 5.2 g/dL) is the only case at Vien gut with full 4-year longitudinal data to illustrate all four phases on an actual patient [12].

Phase Key Results
Phase 1 (Week 1 – Month 3) Simultaneously handled K+ 5.6 + Hb 5.2 + Cortisol 2.1. Follow-up every 1–2 weeks [12].
Phase 2 (Month 3 – 12) GGT 397→180, safe K+, increased Hb. Initiated low-dose Febuxostat. Complete alcohol cessation [12].
Phase 3 (Year 1 – 3) AU reduction of 54%, Fibroscan 23→11 kPa. Grade III splenomegaly completely regressed. Ascites disappeared [12].
Phase 4 (Year 3 – 4) eGFR(CysC) stable at 10–11 – no RRT needed yet. Tophi reduced by 22–31%. Weight 54→65–67 kg [13].

Analyzing the journey of case DTH reveals four consistent architectural blind spots of the fragmented treatment model: (1) identification of secondary adrenal insufficiency due to corticoids; (2) diagnosis of the cause of ALD cirrhosis; (3) management of hyperkalemia in the context of CKD G5 + cirrhosis; (4) comprehensive integrated polypharmacy management [13].

6. DATA-to-operate – Example: quantitative ultrasound monitoring of ascites

Vien gut developed the DATA-to-operate method for the liver axis: quantitative measurement of ascitic fluid through two ultrasound parameters (thickness of free fluid in front of and around the liver, in mm), combined with abdominal circumference (cm) and eGFR(CysC) time series [14]. Result for case DTH: ascites 38/81 mm → 0/0 mm after 4 years; parallel reduction in abdominal circumference; eGFR(CysC) stable at 10–11 without further collapse [15].

7. Role of HOW – DATA-to-operate in each phase

Phase HOW (Operational) DATA-to-operate (Guided Data)
Phase 1 Backup scenarios for complex developments [15]. Warning thresholds, reaction plans, frequent follow-up schedule [15].
Phase 2 Maintain stability, standardized patient training [16]. Milestone reminders, early warning when slipping from the stable zone [16].
Phase 3 Consolidation, reduced contact frequency [16]. Trend dashboards, before-after comparisons [16].
Phase 4 Long-term maintenance, remote support [16]. Tracking achieved goals, rapid reconnection during events [16].

8. Clinical Conductor and Multidisciplinary Team

The Clinical Conductor maintains the vertical axis of the entire treatment plan [16]. The MDT operates as a sensor-response chain: imaging physicians turn images into longitudinal monitoring tools; the lab turns tests into radars to identify breaking points; clinical pharmacists act as safety checkpoints for polypharmacy; and nurses implement checklists and detect red signals [16].

9. Safety Referral Valve

If at any phase a patient exceeds the outpatient safety boundary, the referral valve must be activated immediately [17]. The valve is not just one-way (referring out) but must have a reverse direction: reintegration after inpatient care with a data handover process, post-inpatient monitoring rhythm, and conditions for a stable return to outpatient care [17].

10. Comparison with the Fragmented Treatment Model

International evidence confirms: the fragmented model causes excessive treatment burden and conflicting goals [17]. The WHAT–HOW–DATA-to-operate outpatient treatment plan of Vien gut addresses these gaps through an integrated architecture with a Clinical Conductor, an MDT operating as a sensor-response chain, and a two-way referral valve [17].

Evidence Level: Level IV – proof-of-concept. Full data: DTH Case Report v5.4 CARE (Vien gut, 2026) [18].

References

International Guidelines – WHAT

[1] NICE. Multimorbidity: clinical assessment and management (NG56). NICE, 2016 [18].
[2] KDIGO. 2024 Clinical Practice Guideline for CKD. Kidney Int. 2024; Supplement [18].
[3] FitzGerald JD, et al. 2020 ACR Guideline for Management of Gout. Arthritis Care Res. 2020;72(6):744–760 [18].
[4] McDonagh TA, et al. 2021 ESC Guidelines for heart failure. Eur Heart J. 2021;42(36):3599–3726 [18].
[5] EASL. Clinical Practice Guidelines for decompensated cirrhosis. J Hepatol. 2018;69(2):406–460 [19].
[6] AASLD. Approach to Abnormal Liver Biochemical and Function Tests. AASLD, 2023 [19].
[7] Bornstein SR, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency. J Clin Endocrinol Metab. 2016;101(2):364–389 [19].
[8] Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. J Am Coll Cardiol. 2021;78(22):e187–e285 [19].

Evidence – Limitations of the Fragmented Model

[9] Hughes LD, et al. Guidelines for people not for diseases. Age Ageing. 2013;42(1):62–69 [19].
[10] Muth C, et al. Evidence supporting clinical management of multimorbidity. J Intern Med. 2019;285(3):272–288 [20].
[11] Onder G, et al.; JA-CHRODIS. Multimorbidity management. Health Policy. 2015;119(12):1513–1520 [20].
[12] Jiang S, et al. Care fragmentation and chronic illness outcomes. J Nurs Manag. 2023;2023:3707960 [20].

EXECUTIVE SUMMARY FOR EXPERT REVIEWERS

DOCUMENT B.2 OUTPATIENT TREATMENT PLAN

WHAT – HOW – DATA-to-operate Architecture according to the Vien gut Model: From complex stage control to sustainable maintenance – four treatment phases [4]

Nguyen Dinh Quang • Vien gut Model – March 2026 [4]

1. Problem Statement

The major treatment goals of the Vien gut Model – crystal-free in complicated gout (Goal 1), delaying dialysis for end-stage chronic kidney disease patients with an open window of opportunity (Goal 2), reducing cardiovascular decompensation (Goal 3), and re-compensating liver cirrhosis (Goal 4) – can only be substantially pursued when patients are approached through the WHAT – HOW – DATA-to-operate treatment model [4]. This thinking aligns with the spirit of NICE regarding multimorbidity: not a mechanical summation of single-disease guidelines, but optimizing care, reducing treatment burden, and having a clear coordinator for each patient [4]. Therefore, these treatment goals are not set after many disjointed examinations, but must be initiated from the very first visit [5]. The first visit must be the activation point for the entire integrated operating system – relatively comprehensive examination and diagnosis, identification of pathological spirals, and patient stratification by treatment safety level to choose the appropriate management direction from the start [5].

2. Three-layer Architecture: WHAT – HOW – DATA-to-operate

The outpatient treatment plan in the Vien gut Model is a three-layer structure [5]. Each layer has a distinct and irreplaceable role [5]. The table below summarizes the core content of each layer:

Layer Core Content
WHAT Treatment goals and principles benchmarked from current guidelines: ACR 2020 (gout), KDIGO 2024 (kidney), ESC 2022 (heart), EASL/AASLD (liver) [6].
HOW Clinical operational layer: Clinical Conductor, T1–T4 stratification, polypharmacy management, phase-based scenarios, follow-up rhythm, MDT role, safety referral valve [6].
DATA-to-operate Data set sufficient for action: which target organ is worsening, which spiral is active, whether the patient still has or has lost the window of opportunity, which phase they are in, and if it is time to change phases/refer [6].

This separation of the three layers explains why guidelines (WHAT) alone are insufficient for treating patients with complex multimorbidity: without the HOW layer, physicians know the goals but lack organizational tools; without the DATA-to-operate layer, the system fails to recognize breaking points and windows of opportunity [7]. Vien gut has developed these two layers through 18 years of integrated clinical practice [7].

3. Five Principles for Developing an Outpatient Treatment Plan

Principle Content
1 One patient – one integrated frame of reference: only one Clinical Conductor and one common set of priorities [7].
2 Do not apply single-disease guidelines mechanically: determine if the patient is within, at the margin of, or outside the guideline coverage [8].
3 Prioritize protecting vital organs first, optimize long-term goals later [8].
4 Polypharmacy management is a mandatory component of every treatment plan [8].
5 Decisions based on time-series trends, not single cross-sectional snapshots [8].

These five principles are not administrative conventions but a safety filter: every clinical decision must be checked against them [8]. When a decision violates any principle, the system must stop and re-evaluate before proceeding [8].

4. Structure of Four Treatment Phases

The outpatient treatment plan is organized into four phases [9]. This division into four phases is not for theoretical aesthetics but reflects the 18-year reality of treating complex chronic multimorbidity at Vien gut [9]. Each phase has its own clinical characteristics, objectives, follow-up rhythm, and varying roles for HOW – DATA-to-operate [9].

Phase Main Objective Follow-up Rhythm
Phase 1: Acute Stabilization Control complex developments, re-establish minimum safety margin [9]. Every few days – 2–4 weeks [9].
Phase 2: Titration Maintain stability, prevent re-entry into the spiral, approach verification goals [9]. 3–4 weeks, maximum 3 months [10].
Phase 3: Maintenance Consolidate results, maintain positive trends, reduce risk of relapsing [10]. Maximum 6 months [10].
Phase 4: Crystal-free Evaluation Sustainable maintenance, return to a healthy life [10]. 2–3 months or as needed [10].

Phase 1 (Acute Stabilization) is the most demanding operationally [10]. In this phase, the disease is still complex, the physician is just starting trial treatments, and patients/relatives are still struggling to understand and implement the plan [10]. HOW must have pre-established backup scenarios for common complex developments [10]. From Phase 2 onwards, the focus shifts from emergency control to maintaining stability and standardized patient training [11]. Phase 4 does not mean the end of treatment, but a transition to sustainable maintenance [11].

5. Clinical Illustration – Case DTH: Four phases in a 4-year case / 46 visits

Case DTH (male, 58 years old, gout ~20 years, cirrhosis F4 Child–Pugh B + CKD G5 + adrenal insufficiency + anemia Hb 5.2 g/dL) is the only case at Vien gut with full 4-year longitudinal data to illustrate all four phases on an actual patient [12].

Phase Key Results
Phase 1 (Week 1 – Month 3) Simultaneously handled K+ 5.6 + Hb 5.2 + Cortisol 2.1. Follow-up every 1–2 weeks [12].
Phase 2 (Month 3 – 12) GGT 397→180, safe K+, increased Hb. Initiated low-dose Febuxostat. Complete alcohol cessation [12].
Phase 3 (Year 1 – 3) AU reduction of 54%, Fibroscan 23→11 kPa. Grade III splenomegaly completely regressed. Ascites disappeared [12].
Phase 4 (Year 3 – 4) eGFR(CysC) stable at 10–11 – no RRT needed yet. Tophi reduced by 22–31%. Weight 54→65–67 kg [13].

Analyzing the journey of case DTH reveals four consistent architectural blind spots of the fragmented treatment model: (1) identification of secondary adrenal insufficiency due to corticoids; (2) diagnosis of the cause of ALD cirrhosis; (3) management of hyperkalemia in the context of CKD G5 + cirrhosis; (4) comprehensive integrated polypharmacy management [13].

6. DATA-to-operate – Example: quantitative ultrasound monitoring of ascites

Vien gut developed the DATA-to-operate method for the liver axis: quantitative measurement of ascitic fluid through two ultrasound parameters (thickness of free fluid in front of and around the liver, in mm), combined with abdominal circumference (cm) and eGFR(CysC) time series [14]. Result for case DTH: ascites 38/81 mm → 0/0 mm after 4 years; parallel reduction in abdominal circumference; eGFR(CysC) stable at 10–11 without further collapse [15].

7. Role of HOW – DATA-to-operate in each phase

Phase HOW (Operational) DATA-to-operate (Guided Data)
Phase 1 Backup scenarios for complex developments [15]. Warning thresholds, reaction plans, frequent follow-up schedule [15].
Phase 2 Maintain stability, standardized patient training [16]. Milestone reminders, early warning when slipping from the stable zone [16].
Phase 3 Consolidation, reduced contact frequency [16]. Trend dashboards, before-after comparisons [16].
Phase 4 Long-term maintenance, remote support [16]. Tracking achieved goals, rapid reconnection during events [16].

8. Clinical Conductor and Multidisciplinary Team

The Clinical Conductor maintains the vertical axis of the entire treatment plan [16]. The MDT operates as a sensor-response chain: imaging physicians turn images into longitudinal monitoring tools; the lab turns tests into radars to identify breaking points; clinical pharmacists act as safety checkpoints for polypharmacy; and nurses implement checklists and detect red signals [16].

9. Safety Referral Valve

If at any phase a patient exceeds the outpatient safety boundary, the referral valve must be activated immediately [17]. The valve is not just one-way (referring out) but must have a reverse direction: reintegration after inpatient care with a data handover process, post-inpatient monitoring rhythm, and conditions for a stable return to outpatient care [17].

10. Comparison with the Fragmented Treatment Model

International evidence confirms: the fragmented model causes excessive treatment burden and conflicting goals [17]. The WHAT–HOW–DATA-to-operate outpatient treatment plan of Vien gut addresses these gaps through an integrated architecture with a Clinical Conductor, an MDT operating as a sensor-response chain, and a two-way referral valve [17].

Evidence Level: Level IV – proof-of-concept. Full data: DTH Case Report v5.4 CARE (Vien gut, 2026) [18].

References

International Guidelines – WHAT

[1] NICE. Multimorbidity: clinical assessment and management (NG56). NICE, 2016 [18].
[2] KDIGO. 2024 Clinical Practice Guideline for CKD. Kidney Int. 2024; Supplement [18].
[3] FitzGerald JD, et al. 2020 ACR Guideline for Management of Gout. Arthritis Care Res. 2020;72(6):744–760 [18].
[4] McDonagh TA, et al. 2021 ESC Guidelines for heart failure. Eur Heart J. 2021;42(36):3599–3726 [18].
[5] EASL. Clinical Practice Guidelines for decompensated cirrhosis. J Hepatol. 2018;69(2):406–460 [19].
[6] AASLD. Approach to Abnormal Liver Biochemical and Function Tests. AASLD, 2023 [19].
[7] Bornstein SR, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency. J Clin Endocrinol Metab. 2016;101(2):364–389 [19].
[8] Gulati M, et al. 2021 AHA/ACC Guideline for Chest Pain. J Am Coll Cardiol. 2021;78(22):e187–e285 [19].

Evidence – Limitations of the Fragmented Model

[9] Hughes LD, et al. Guidelines for people not for diseases. Age Ageing. 2013;42(1):62–69 [19].
[10] Muth C, et al. Evidence supporting clinical management of multimorbidity. J Intern Med. 2019;285(3):272–288 [20].
[11] Onder G, et al.; JA-CHRODIS. Multimorbidity management. Health Policy. 2015;119(12):1513–1520 [20].
[12] Jiang S, et al. Care fragmentation and chronic illness outcomes. J Nurs Manag. 2023;2023:3707960 [20].

Electronic information portal providing specialized services (medicine and science & technology) of Vien Gut Company Limited. Compliant with Article 24, Clause 2 of Decree No. 147/2024/ND-CP, GDPR, and CCPA/CPRA.

COMPLIANT WITH DECREE NO. 147/2024/ND-CP (VIETNAM), GDPR (EU), AND CCPA/CPRA (U.S.).